Capturing Infectious COVID-19 Asymptomatic Cases in Singapore

Becton, Dickinson and Company (BD)

Status: Withdrawn

Conditions: Covid19; SARS CoV-2

Treatments: Diagnostic Test: viral culture; Diagnostic Test: BD Veritor Plus System for Rapid Detection of SARS CoV-2; Diagnostic Test: rt-PCR

Study type: Observational

Funder types: Industry

Identifiers

NCT04812327

SGP-21AsymVer-01

Details and patient eligibility

About

This study is being conducted to assess the performance of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2, used in serial testing, in identification of infectious, asymptomatic individuals. This information may be used to inform development of an effective testing strategy by policy makers.

Full description

This multi-center, prospective, observational, diagnostic evaluation study is designed to assess the performance of the BD Veritor System in the detection of SARS-CoV-2 in asymptomatic individuals compared to viral culture and a commercially available RT-PCR assay over multiple testing time points. The study will enroll a minimum of 150 asymptomatic, adult participants who test positive for SARS-CoV-2 during community/traveler screening procedures.

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female ≥21 years of age at the time of informed consent
2. Has a positive screening test for SARS-CoV-2 by RT-PCR
3. Is asymptomatic for COVID-19 on the day of their positive screening test (may have symptoms on the actual day of study enrollment)
4. Is expected to remain at the study site for the full 6-day study period
5. Willing and able to complete all study required procedures
6. Provision of signed and dated informed consent form

Exclusion criteria

1. History of frequent or difficult to control nosebleeds within the 14 days prior to study participation
2. If, at the discretion of the Investigator, involvement in the study is likely to jeopardize the subject's health or their current or future medical treatment

Trial design

0 participants in 1 patient group

Prospective Observational Diagnostic Evaluation

Description:

Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is \>30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.

Treatment:

Diagnostic Test: viral culture

Diagnostic Test: rt-PCR

Diagnostic Test: BD Veritor Plus System for Rapid Detection of SARS CoV-2